Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388210 | 0.84 | NPC1 (0.44) | GAANPC1RAB9AL3MBTL1POLB | |
| SCHEMBL8883980 | 0.84 | ALDH1A1 (0.35) | GAANPC1RAB9AL3MBTL1POLB | |
| SCHEMBL7524003 | 0.80 | NPC1 (0.36) | GAANPC1RAB9AL3MBTL1POLB | |
| SCHEMBL6542130 | 0.79 | NPC1 (0.41) | GAANPC1RAB9AL3MBTL1POLB | |
| SCHEMBL10545379 | 0.77 | MEN1 (0.40) | GAANPC1RAB9AL3MBTL1POLB | |
| SCHEMBL8883410 | 0.77 | KDM4E (0.38) | RAB9APOLBKDM4EALDH1A1CYP11B2 | |
| SCHEMBL16327606 | 0.76 | L3MBTL1 (0.47) | GAANPC1RAB9AL3MBTL1POLB | |
| SCHEMBL27412940 | 0.73 | HTT (0.49) | GAAPOLBKDM4EALDH1A1CYP3A4 | |
| SCHEMBL10884861 | 0.72 | ALDH1A1 (0.35) | GAAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8019417 | 0.71 | KDM4E (0.38) | GAAKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427619-B2 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | BURZYNSKI STANISLAW R | 2008-09-23 | — | — | US | claimed |
| EP-1450781-B1 | FORMULATION OF AMINO ACIDS AND RIBOFLAVIN USEFUL TO REDUCE TOXIC EFFECTS OF CYTOTOXIC CHEMOTHERAPY | BURZYNSKI STANISLAW R (US) | 2006-06-21 | — | — | EP | claimed |
| EP-0906088-B1 | LIPOSOMAL ANTINEOPLASTON THERAPIES WITH MARKEDLY IMPROVED ANTINEOPLASTIC ACTIVITY | BURZYNSKI STANISLAW R (US) | 2005-11-23 | — | — | EP | claimed |
| US-20050182064-A1 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | BURZYNSKI STANISLAW R (US) | 2005-08-18 | — | — | US | claimed |
| EP-1450781-A1 | FORMULATION OF AMINO ACIDS AND RIBOFLAVIN USEFUL TO REDUCE TOXIC EFFECTS OF CYTOTOXIC CHEMOTHERAPY | Burzynski, Stanislaw R. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045372-A1 | FORMULATION OF AMINO ACIDS AND RIBOFLAVIN USEFUL TO REDUCE TOXIC EFFECTS OF CYTOTOXIC CHEMOTHERAPY | BURZYNSKI STANISLAW R (US) | 2003-06-05 | — | — | WO | claimed |
| US-20030105104-A1 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | BURZYNSKI STANISLAW R (US) | 2003-06-05 | — | — | US | claimed |
| EP-0197358-B1 | TOPICAL USE OF 3-PHENYLACETYLAMINO-2,6-PIPERIDINEDIONE FOR TREATMENT OF SKIN WRINKLES AND HYPERPIGMENTATION | BURZYNSKI, Stanislaw R. (US) | 1990-05-23 | — | — | EP | claimed |
| EP-0197358-A2 | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation | BURZYNSKI, Stanislaw R. (US) | 1986-10-15 | — | — | EP | claimed |
| US-4593038-A | Applying to skin | BURZYNSKI STANISLAW R | 1986-06-03 | — | — | US | claimed |
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250387362-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | BURZYNSKI STANISLAW R (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250213515-A1 | METHODS FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | BURZYNSKI STANISLAW R (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4568663-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | Burzynski, Stanislaw R. (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-0197358-A2 | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation | BURZYNSKI, Stanislaw R. (US) | 1986-10-15 | — | — | EP | disclosed |
| EP-0197358-A2 | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation | BURZYNSKI, Stanislaw R. (US) | 1986-10-15 | — | — | EP | disclosed |
| US-4593038-A | Applying to skin | BURZYNSKI STANISLAW R | 1986-06-03 | — | — | US | disclosed |
| US-4593038-A | Applying to skin | BURZYNSKI STANISLAW R | 1986-06-03 | — | — | US | disclosed |
| US-4593038-A | Applying to skin | BURZYNSKI STANISLAW R | 1986-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213515-A1 | METHODS FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | IDH3B, IDH1, IDH2 | GAA 87/4885NPC1 3063/4885RAB9A 2057/4885 |
| US-20250387362-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | SLC25A1, GOT2, FOLH1 | GAA 382/4885NPC1 877/4885RAB9A 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.